🚀 VC round data is live in beta, check it out!
Standard BioTools Valuation Multiples
Discover revenue and EBITDA valuation multiples for Standard BioTools and similar public comparables like Medios, Universal Vision, Delcath Systems, ClearPoint Neuro and more.
Standard BioTools Overview
About Standard BioTools
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
Founded
1999
HQ
Employees
818
Website
Financials (LTM)
EV
$207M
Standard BioTools Financials
Standard BioTools reported last 12-month revenue of $84M and negative EBITDA of ($52M).
In the same LTM period, Standard BioTools generated $42M in gross profit, ($52M) in EBITDA losses, and had net loss of ($68M).
Revenue (LTM)
Standard BioTools P&L
In the most recent fiscal year, Standard BioTools reported revenue of $85M and EBITDA of ($62M).
Standard BioTools expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $84M | XXX | $85M | XXX | XXX | XXX |
| Gross Profit | $42M | XXX | $43M | XXX | XXX | XXX |
| Gross Margin | 50% | XXX | 50% | XXX | XXX | XXX |
| EBITDA | ($52M) | XXX | ($62M) | XXX | XXX | XXX |
| EBITDA Margin | (62%) | XXX | (73%) | XXX | XXX | XXX |
| EBIT Margin | (115%) | XXX | (109%) | XXX | XXX | XXX |
| Net Profit | ($68M) | XXX | ($75M) | XXX | XXX | XXX |
| Net Margin | (81%) | XXX | (88%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Standard BioTools Stock Performance
Standard BioTools has current market cap of $364M, and enterprise value of $207M.
Market Cap Evolution
Standard BioTools' stock price is $0.93.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $207M | $364M | 0.0% | XXX | XXX | XXX | $-0.19 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialStandard BioTools Valuation Multiples
Standard BioTools trades at 2.5x EV/Revenue multiple, and (4.0x) EV/EBITDA.
EV / Revenue (LTM)
Standard BioTools Financial Valuation Multiples
As of April 20, 2026, Standard BioTools has market cap of $364M and EV of $207M.
Equity research analysts estimate Standard BioTools' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Standard BioTools has a P/E ratio of (5.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $364M | XXX | $364M | XXX | XXX | XXX |
| EV (current) | $207M | XXX | $207M | XXX | XXX | XXX |
| EV/Revenue | 2.5x | XXX | 2.4x | XXX | XXX | XXX |
| EV/EBITDA | (4.0x) | XXX | (3.3x) | XXX | XXX | XXX |
| EV/EBIT | (2.1x) | XXX | (2.2x) | XXX | XXX | XXX |
| EV/Gross Profit | 4.9x | XXX | 4.9x | XXX | XXX | XXX |
| P/E | (5.3x) | XXX | (4.9x) | XXX | XXX | XXX |
| EV/FCF | (3.5x) | XXX | (2.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Standard BioTools Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Standard BioTools Margins & Growth Rates
Standard BioTools' revenue in the last 12 month declined by (2%).
Standard BioTools' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.2M for the same period.
Standard BioTools' rule of 40 is (39%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Standard BioTools' rule of X is (46%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Standard BioTools Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (2%) | XXX | (4%) | XXX | XXX | XXX |
| EBITDA Margin | (62%) | XXX | (73%) | XXX | XXX | XXX |
| EBITDA Growth | (54%) | XXX | (55%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (39%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (46%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 29% | XXX | 30% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 159% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Standard BioTools Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Standard BioTools | XXX | XXX | XXX | XXX | XXX | XXX |
| Medios | XXX | XXX | XXX | XXX | XXX | XXX |
| Universal Vision | XXX | XXX | XXX | XXX | XXX | XXX |
| Delcath Systems | XXX | XXX | XXX | XXX | XXX | XXX |
| ClearPoint Neuro | XXX | XXX | XXX | XXX | XXX | XXX |
| VieMed | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Standard BioTools M&A Activity
Standard BioTools acquired XXX companies to date.
Last acquisition by Standard BioTools was on XXXXXXXX, XXXXX. Standard BioTools acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Standard BioTools
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialStandard BioTools Investment Activity
Standard BioTools invested in XXX companies to date.
Standard BioTools made its latest investment on XXXXXXXX, XXXXX. Standard BioTools invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Standard BioTools
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Standard BioTools
| When was Standard BioTools founded? | Standard BioTools was founded in 1999. |
| Where is Standard BioTools headquartered? | Standard BioTools is headquartered in United States. |
| How many employees does Standard BioTools have? | As of today, Standard BioTools has over 818 employees. |
| Who is the CEO of Standard BioTools? | Standard BioTools' CEO is Michael Egholm. |
| Is Standard BioTools publicly listed? | Yes, Standard BioTools is a public company listed on Nasdaq. |
| What is the stock symbol of Standard BioTools? | Standard BioTools trades under LAB ticker. |
| When did Standard BioTools go public? | Standard BioTools went public in 2011. |
| Who are competitors of Standard BioTools? | Standard BioTools main competitors are Medios, Universal Vision, Delcath Systems, ClearPoint Neuro. |
| What is the current market cap of Standard BioTools? | Standard BioTools' current market cap is $364M. |
| What is the current revenue of Standard BioTools? | Standard BioTools' last 12 months revenue is $84M. |
| What is the current revenue growth of Standard BioTools? | Standard BioTools revenue growth (NTM/LTM) is (2%). |
| What is the current EV/Revenue multiple of Standard BioTools? | Current revenue multiple of Standard BioTools is 2.5x. |
| Is Standard BioTools profitable? | No, Standard BioTools is not profitable. |
| What is the current EBITDA of Standard BioTools? | Standard BioTools has negative EBITDA and is not profitable. |
| What is Standard BioTools' EBITDA margin? | Standard BioTools' last 12 months EBITDA margin is (62%). |
| What is the current EV/EBITDA multiple of Standard BioTools? | Current EBITDA multiple of Standard BioTools is (4.0x). |
| What is the current FCF of Standard BioTools? | Standard BioTools' last 12 months FCF is ($59M). |
| What is Standard BioTools' FCF margin? | Standard BioTools' last 12 months FCF margin is (70%). |
| What is the current EV/FCF multiple of Standard BioTools? | Current FCF multiple of Standard BioTools is (3.5x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.